Lobular carcinoma in situ is a breast change that is sometimes seen in a breast biopsy. The presence of LCIS increases the risk of each of them developing invasive breast cancer in the future, so careful monitoring is important. Breast changes are a form of lobular tumor formation.

Lobular carcinoma in situ. LCIS ​​can be said to be the only anomaly. Women with LCIS have an increased risk of breast cancer, so close monitoring is essential. It is important to monitor both breasts closely because women with LCIS also have an increased risk of cancer in both breasts. Lobular carcinoma in situ can be present on one or both breasts, but it is usually not visible on mammograms . In order to get the maximum protection benefit from this operation, both breasts will be removed because LCIS increases the risk of breast cancer for both. Your first breast cancer letter will be sent to your inbox shortly and will contain information about treatment, diagnosis, surgery, and how the Mayo Clinic breast cancer team conducts personalized care for Breast cancer in the future. Write down your medical history, including information about any breast biopsy or benign breast disease that  have been  previously diagnosed. Consider a family history of breast cancer or other cancers, especially related lobular carcinoma in situ.

Abnormal growth of cells in the lining of the breast are called lobules. In a 2017 study comparing the risk factor associations between breast cancer and diseases that may lead to breast cancer, LCIS found an association between hormone replacement therapy during menopause and LCIS. The authors of the study pointed out that the risk factors of LCIS are the factors that doctors consider DCIS precancerous lesions, but it is not clear whether DCIS is definitely breast cancer or just a risk factor for breast cancer. Preventive bilateral mastectomy is the removal of both breasts to reduce the risk of breast cancer. In order to reduce the risk of breast cancer, the doctor may also recommend that a person take estrogen blocking or estrogen lowering drugs, because hormones affect the growth of breast cancer cells. A 2017 study compared the risk factor associations between breast cancer and diseases that may cause breast cancer, such as LCIS, and found an association between menopausal use of hormone replacement therapy and LCIS. The study authors found that the risk factors for LCIS are similar to breast cancer.

Doctors believe that DCIS is a precancerous lesion, but it is not clear whether LCIS is actually a precancerous lesion or just a risk factor for breast cancer. According to the American Cancer Society, since LCIS shows no signs, doctors usually find it through a biopsy of a nearby breast disease. Preventive bilateral mastectomy is the removal of both breasts to reduce the risk of breast cancer. To reduce the risk of breast cancer, a doctor may also recommend a person to take estrogen-blocking or estrogen-lowering drugs, because hormone lobular carcinoma in situ (LCIS) accounts for 5.3% of in situ specimens. It is considered a lower risk Progressed to invasive lobular breast cancer (CLI). There is currently no standardized method to treat LCIS patients. Our goal is to determine the impact of surgery and radiotherapy on the survival outcome of LCIS. The LCIS cases from 2004 to 2013 were analyzed based on the current surveillance, epidemiology and results (SEER) database. Clinical and pathological characteristics of 16,002 patients from 2004 to 2013. Treatment options include no surgery (NS), lumpectomy only (LA), lumpectomy combined with radiotherapy (LRT), mastectomy only (MA), and mastectomy combined with radiotherapy (MRI)). The Kaplan-Meier method was used to calculate overall survival (OS). Univariate and multivariate analyses were performed using treatment variables, race, hormone receptor status, severity, and age. The median follow-up time for 16,002 patients was 54 months. Patients treated with LA had higher OS for NS (P = 0.001), MA (P and <0.001), and MRI P = 0.LRT only had a higher OS in MRI (P = 0.009). There was no statistical significance between LA and LRT (P = 0.317). The improvement in OS was also associated with younger age (P ylt; 0.001) and progesterone receptor positive (P = 0.001). Black patients had the worst OS (P <0.001).This indicates that among LCIS patients, most doctors are more likely to perform surgery than non-surgical treatments. Many studies have reported pathological improvement rates after surgical biopsy of LCIS diagnosed as CNB. However, the results are quite different. In another article, the author showed that the incidence of IBC in LCIS patients was 7.1% within 10 years . In addition, the 2017 NCCN guidelines stated that surgical resection is recommended after LCIS has diagnosed BAC . Therefore, most of the LA in this study corresponds to current clinical treatment strategies. As for age, analysis shows that it does not play a role in the choice of treatment options.

Doctors are not aware of the exact cause of LCIS, but studies suggest the risk factors are similar to those of breast cancer.